Chengdu Tianzhiyi Shangpin Pharmaceutical Technology

Chengdu Tianzhiyi Shangpin Pharmaceutical Technology is a Chinese biotechnology company focused on the research and development of innovative small molecule therapeutics. The company primarily targets metabolic disorders, with a specific focus on developing oral treatments for type 2 diabetes and obesity. Their lead research efforts involve dual agonists for the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR). By leveraging small molecule chemistry, the company aims to provide more convenient alternatives to injectable peptide-based metabolic therapies. Chengdu Tianzhiyi Shangpin operates out of the Chengdu High-tech Zone, a major hub for pharmaceutical innovation in China.